TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26329381
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (CIT) with dextromethorphan (150 mg) and anodal/cathodal tDCS
Study: 26329381
Drug: Placebo (PLC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLC) medication with anodal or cathodal tDCS
Study: 24629063
Drug: 12-week exercise
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week exercise intervention with four group sessions and home exercises three times a week, with weekly telephone follow-up during eight weeks without group sessions.
Study: 20605552
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy and light massage control
Study: 7608436
Drug: Heparin (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5,000 IU) before thrombolytic treatment with saruplase (20 mg bolus + 60 mg infusion over 60 min)
Study: 7608436
Drug: Placebo before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before thrombolytic treatment with saruplase (20 mg bolus + 60 mg infusion over 60 min)
Study: 7608436
Drug: Heparin (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5,000 IU) before thrombolytic treatment with saruplase
Study: 7608436
Drug: Placebo before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before thrombolytic treatment with saruplase
Study: 2789272
Drug: High‐dose leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐dose leucovorin plus 5‐FU (arm B)
Study: 2789272
Drug: Sequential methotrexate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential methotrexate, 5‐FU, and leucovorin (arm C)
Study: 342557
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (6 sessions of verbal self-instructions via modeling with response-cost contingent upon errors)
Study: 342557
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (similar training without specific treatment)
Study: 30711698
Drug: 2-dose HPV
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose HPV vaccine
Study: 30711698
Drug: 3-dose HPV
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose HPV vaccine
Study: 23899172
Drug: Genistein (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein (54 mg/day) for 6 months
Study: 19958521
Drug: Anatibant (low,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anatibant (low, medium, or high dose)
Study: 19958521
Drug: Anatibant (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anatibant (any dose)
Study: 16430668
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (trigger at 8 g/dl)
Study: 16430668
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (trigger at 10 g/dl)
Study: 15582838
Drug: Oxcarbazepine (OXC)
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine (OXC) - 1200 mg
Study: 15582838
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) - 360 mg
Study: 10651210
Drug: Cibenzoline 25
Normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline 25 mg/day
Study: 10651210
Drug: Cibenzoline 50
Normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline 50 mg/day
Study: 10651210
Drug: Cibenzoline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (25 and 50 mg/day)
Study: 8450580
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 g polyglucose, Polycose)
Study: 2945499
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate (CTM) 12 mg
Study: 2945499
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of loratadine
Study: 3041936
Drug: Carteolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol (2.5 to 5.0 mg/d for an average of 328 days)
Study: 30760406
Drug: TKIs treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKIs treatment (first-line)
Study: 28697773
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment for 5 days
Study: 25040321
Drug: Propofol injected
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol injected intravenously in 30 to 40 mg boluses, followed by 10 to 20 mg intermittent bolus doses to sedate the patients to Ramsey score of 3 to 4.
Study: 12766621
Drug: 1.32 ml
Normalized name: 1.32 ML Invega 311 MG/ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.32 ml of 95% alcohol per kilogram of body weight, mixed with orange juice
Study: 3514368
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of PGE2 in 2.5 ml of Triacetin gel
Study: 3514368
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PGE2 gel with conventional oxytocin induction
Study: 27645244
Drug: Narlaprevir (NVR)
Normalized name: Paritaprevir
DrugBank: Narlaprevir (DB14760)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Narlaprevir (NVR) 200 mg
Study: 27645244
Drug: Narlaprevir (NVR)
Normalized name: Paritaprevir
DrugBank: Narlaprevir (DB14760)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Narlaprevir (NVR) 100 mg with Ritonavir (RTV) 100 mg
Study: 25170231
Drug: Tandospirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandospirone (10 mg thrice daily) and pinaverium (50 mg thrice daily)
Study: 25170231
Drug: Pinaverium (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium (50 mg thrice daily) and placebo
Study: 12357161
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g acetaminophen
Study: 12357161
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g acetaminophen and 50 mg rofecoxib
Study: 12357161
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg vitamin C (placebo)
Study: 10204818
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (60 mg twice daily) for 8 weeks
Study: 2182300
Drug: Intravenous ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketanserin
Study: 6446424
Drug: Intra-amniotic injection
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic injection of dehydroepiandrosterone sulphate (DHEA-S) (100-200 mg)
Study: 6446424
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of dehydroepiandrosterone sulphate (DHEA-S) (100 mg)
Study: 29091327
Drug: Peg‐IFN‐α‐2a add‐on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN‐α‐2a add‐on therapy
Study: 16135583
Drug: Intrauterine 5‐mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine 5‐mL 2% lidocaine
Study: 12042267
Drug: 150 microg
Normalized name: Norgestrel 150 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 microg desogestrel p.o. daily for 24 weeks with 400 mg testosterone pellets s.c. on day 1 and at 12 weeks
Study: 12042267
Drug: 300 microg
Normalized name: Voglibose 300 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 microg desogestrel p.o. daily for 24 weeks with 400 mg testosterone pellets s.c. on day 1 and at 12 weeks
Study: 9543120
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment (0.3 mg/kg x week, mean duration = 41 months)
Study: 8304654
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral acyclovir (800 mg four times daily)
Study: 8304654
Drug: Preemptive, short-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive, short-course ganciclovir therapy (5 mg/kg intravenously twice daily for 7 days if CMV shedding occurred)
Study: 2729815
Drug: lyophilized collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: lyophilized collagen pads as adjunctive treatment
Study: 29247643
Drug: LFS‐01 (sulforaphene)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFS‐01 (sulforaphene) treatment
Study: 23073723
Drug: Buspirone 10
Normalized name: busPIRone 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 10 mg/day
Study: 21282192
Drug: DDMM (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDMM (2 doses of DNA followed by 2 doses of rMVA)
Study: 21282192
Drug: DMM (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMM (1 dose of DNA followed by 2 doses of rMVA)
Study: 21282192
Drug: MMM (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMM (3 doses of rMVA)
Study: 21282192
Drug: 1/10th-dose DDMM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/10th-dose DDMM regimen
Study: 15080848
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously once daily for up to 42 days
Study: 9312206
Drug: Intramuscular SCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular SCT (IM)
Study: 7865076
Drug: NaF dentifrices
Normalized name: DENTIFRICES
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF dentifrices (1000 or 1500 micrograms F/g)
Study: 7865076
Drug: Na2FPO3 dentifrices
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Na2FPO3 dentifrices (1000 or 1500 micrograms F/g)
Study: 2511277
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms of recombinant IFN-gamma given once weekly
Study: 240112
Drug: Beta adrenergic
Normalized name: Beta adrenergic receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta adrenergic blocking agents
Study: 240112
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of beta adrenergic blocking agents with peripheral vasodilators (e.g., hydrallazine, prazosin)
Study: 31513552
Drug: Community empowerment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community empowerment model of combination HIV prevention (Project Shikamana)
Study: 20079922
Drug: 0.59-mg FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.59-mg FA intravitreal implant
Study: 15983798
Drug: Modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200 mg + Clonidine 0.2 mg
Study: 10659924
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (estradiol 50 microg/day) combined with oral medroxyprogesterone acetate (MPA) 10 mg/day for 12 days/month
Study: 10659924
Drug: Tibolone tablets
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone tablets 2.5 mg/day
Study: 31393444
Drug: Intramuscular Retinalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Retinalamin injections
Study: 26105520
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract (PE) 900 mg daily before surgery
Study: 23182608
Drug: Remifentanil 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.50 μg/kg
Study: 23182608
Drug: Remifentanil 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1.0 μg/kg
Study: 23182608
Drug: Remifentanil 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1.25 μg/kg
Study: 16639483
Drug: Bone sparing
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone sparing agents (hormone therapy, bisphosphonates, PTH 1‐34)
Study: 9261583
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis with cefazolin
Study: 8337215
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate infusion during panic attack
Study: 3013442
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (M) with VAC (vincristine, doxorubicin, and cyclophosphamide) at a lower dosage, given every 4 weeks for 8 courses.
Study: 3013442
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance chemotherapy (NM), no further treatment until relapse.
Study: 26376111
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg PD‐0360324
Study: 26376111
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg PD‐0360324
Study: 26376111
Drug: PD‐0360324 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD‐0360324 (both doses)
Study: 20455761
Drug: Nonnucleoside reverse
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonnucleoside reverse transcriptase inhibitors (NNRTIs) - nevirapine (NVP) and efavirenz (EFV)
Study: 15749485
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 50 mg on days 5-9
Study: 11025237
Drug: Subarachnoid injection
Normalized name: TETRACAINE HYDROCHLORIDE 10 mg in 1 mL SUBARACHNOID INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid injection of 12 mg hyperbaric bupivacaine
Study: 6666218
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (40 mg orally every 6 h for 3 months)
Study: 6666218
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (initial dose of 40 mg orally)
Study: 6666218
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral isosorbide dinitrate (40 mg every 6 h)
Study: 29542262
Drug: Intensive counseling,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive counseling, pharmacotherapy, text‐messaging, and financial incentives
Study: 22956863
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg PBE supplementation once daily
Study: 22956863
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg PBE supplementation once daily
Study: 17532750
Drug: MMF dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF dose, MPA‐AUC, and the 2 h AUCs of MPAG and AcMPAG
Study: 3347071
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of diphenhydramine and 300 mg of cimetidine
Study: 27618657
Drug: Pancreatic exocrine
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic exocrine replacement therapy (PERT) consisting of 6-9 capsules of pancreatin (457.7 mg/capsule), taken two capsules three times daily during main meals and one capsule up to three times daily for snacks
Study: 22486159
Drug: Crushed lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crushed lisinopril
Study: 12419743
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (FEC: fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), cyclophosphamide 500 mg/m(2))
Study: 12419743
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (FEC)
Study: 7582281
Drug: salbutamol and
Normalized name: salbutamol and budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol and budesonide combination
Study: 27998620
Drug: Tocilizumab, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab, an interleukin‐6 receptor‐alpha inhibitor
Study: 25917295
Drug: Intensive Short-Term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Short-Term Dynamic (ISTDP) residential treatment program
Study: 25917295
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (wait-list control)
Study: 19524334
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with agalsidase alpha or agalsidase beta
Study: 15994387
Drug: montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: montelukast 10 mg q.d.
Study: 12568841
Drug: Immediate oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate oral contraceptive start
Study: 12568841
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral contraceptive start
Study: 1757831
Drug: Endotracheal suction
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endotracheal suction with saline instillation (0.25-0.5 ml)
Study: 6624697
Drug: alpha‐tocopherol supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐tocopherol supplement of 800 IU
Study: 6624697
Drug: beta‐carotene supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐carotene supplement of 30 mg (5000 retinol equivalents)
Study: 6624697
Drug: retinyl palmitate
Normalized name: Retinyl palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: retinyl palmitate supplement of 25,000 IU (13,750 retinol equivalents)
Study: 23747131
Drug: Concomitant therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy: omeprazole 20mg, amoxicillin 1g, clarithromycin 500 mg, and tinidazole 500 mg for 5 days
Study: 23747131
Drug: Sequential therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy: omeprazole 20mg and amoxicillin 1g for 5 days followed by omeprazole 20mg, clarithromycin 500 mg, and tinidazole 500 mg for 5 days
Study: 23747131
Drug: Hybrid therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid therapy: omeprazole 20mg, and amoxicillin 1g for 7 days followed by omeprazole 20mg, amoxicillin 1g, clarithromycin 500 mg, and tinidazole 500 mg for 7 days
Study: 23747131
Drug: Second-line therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line therapy: omeprazole 20mg, levofloxacin 250 mg, and amoxicillin 1g, all given twice daily for 10 days
Study: 20665553
Drug: Open-label treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label treatment
Study: 19722254
Drug: 3,4-Diaminopyridine (DAP)
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3,4-Diaminopyridine (DAP) up to 75-80 mg/day
Study: 12131981
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (mentholated deionized water)
Study: 10613374
Drug: Tablet splitting
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet splitting using a tablet splitter
Study: 10613374
Drug: Tablet splitting
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet splitting
Study: 1747217
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of elemental calcium in the form of oystershell electrolysate (AA calcium)
Study: 6186187
Drug: Levamisole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (2.5 mg/kg/dose)
Study: 24679444
Drug: IAI 2
Normalized name: Intravitreal aflibercept injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAI 2 mg (IAI 2Q4)
Study: 20060571
Drug: Road traffic
Normalized name: Road to Wellness KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Road traffic noise exposure (n=280, L(eq,24h)=67±2dB(A))
Study: 20060571
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=379, L(eq,24h)=58.7±6dB(A))
Study: 17546842
Drug: Flaxseed flour
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed flour (30 g/day, 5 g of alpha-linolenic acid)
Study: 12058009
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment initiated in early adolescence
Study: 12058009
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment initiated in later adolescence
Study: 8577212
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg o.a.d.
Study: 8577212
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.i.d.
Study: 8577212
Drug: Lansoprazole 45
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 45 mg b.i.d.
Study: 8577212
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg b.i.d.
Study: 2225893
Drug: Paste without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paste without antibiotics applied to the oropharynx (Control group).
Study: 371057
Drug: Clemastine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine, 1 mg/ml
Study: 24444658
Drug: Daclatasvir (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) twice-daily (DUAL A1)
Study: 24444658
Drug: Daclatasvir (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) once-daily (DUAL A2)
Study: 24444658
Drug: Daclatasvir (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) twice-daily + PegIFN/RBV (QUAD B1)